1.85 USD
+0.06
3.35%
At close Dec 20, 4:00 PM EST
After hours
1.85
+0.00
0.00%
1 day
3.35%
5 days
-3.14%
1 month
1.09%
3 months
6.94%
6 months
1.09%
Year to date
-35.09%
1 year
-33.45%
5 years
-32.97%
10 years
-75.40%
 

About: Accuray Inc is a radiation oncology company that develops, manufactures, sells and supports precise, innovative treatment solutions which set the standard of radiation therapy care with the aim of helping patients live better lives. The company's technology, The CyberKnife, is used to treat multiple types of cancer and tumors throughout the body. The CyberKnife Systems automatically track, detect and correct for a tumor and patient movement in real-time during the procedure, enabling delivery of precise, high dose radiation with sub-millimetre accuracy while patients breathe normally, without manual user intervention.

Employees: 987

0
Funds holding %
of 6,809 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

100% more call options, than puts

Call options by funds: $48K | Put options by funds: $24K

85% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 13

12% more repeat investments, than reductions

Existing positions increased: 37 | Existing positions reduced: 33

10% more funds holding

Funds holding: 115 [Q2] → 126 (+11) [Q3]

4% less capital invested

Capital invested by funds: $104M [Q2] → $99.2M (-$4.34M) [Q3]

2.23% less ownership

Funds ownership: 57.35% [Q2] → 55.12% (-2.23%) [Q3]

50% less funds holding in top 10

Funds holding in top 10: 2 [Q2] → 1 (-1) [Q3]

Research analyst outlook

We haven’t received any recent analyst ratings for ARAY.

Financial journalist opinion

Based on 5 articles about ARAY published over the past 30 days

Positive
Zacks Investment Research
2 days ago
ARAY Stock Falls Despite Positive Data of CyberKnife in Treating BSM
Accuray announces positive study data for its CyberKnife System in treating brainstem metastases.
ARAY Stock Falls Despite Positive Data of CyberKnife in Treating BSM
Neutral
PRNewsWire
3 days ago
New Data Indicates the CyberKnife® System Can Provide a Safe and Effective Treatment Option to Control Brainstem Metastases, an Extremely Challenging Location to Treat
Study Builds on Extensive Published Literature Highlighting the Benefits of the CyberKnife System in the Treatment of a Wide Range of Neurological Indications MADISON, Wis., Dec. 18, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today an international retrospective multicenter analysis found that radiosurgery (SRS) and fractionated stereotactic radiotherapy (FSRT), delivered with the CyberKnife® System, can provide an effective and time-saving treatment option for brainstem metastases (BSM).
New Data Indicates the CyberKnife® System Can Provide a Safe and Effective Treatment Option to Control Brainstem Metastases, an Extremely Challenging Location to Treat
Positive
Zacks Investment Research
5 days ago
Looking for a Fast-paced Momentum Stock at a Bargain? Consider Accuray (ARAY)
If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Accuray (ARAY) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.
Looking for a Fast-paced Momentum Stock at a Bargain? Consider Accuray (ARAY)
Positive
Zacks Investment Research
1 week ago
Here's Why You Should Add Accuray Stock in Your Portfolio Now
ARAY's solid product demand and revenue growth raise optimism about the stock.
Here's Why You Should Add Accuray Stock in Your Portfolio Now
Neutral
PRNewsWire
3 weeks ago
Accuray Incorporated Reports Inducement Award Under NASDAQ Listing Rules
MADISON, Wis. , Nov. 26, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported, as required by NASDAQ Listing Rules, equity inducement awards to Mike Murphy, the company's new Vice President, Corporate Controller.
Accuray Incorporated Reports Inducement Award Under NASDAQ Listing Rules
Positive
Zacks Investment Research
1 month ago
Accuray Q1 Earnings Meet Estimates, Sales Beat, Gross Margin Shrinks
ARAY's first-quarter fiscal 2025 earnings meet estimates. Both the top and bottom lines deteriorate year over year.
Accuray Q1 Earnings Meet Estimates, Sales Beat, Gross Margin Shrinks
Neutral
Seeking Alpha
1 month ago
Accuray Incorporated (ARAY) Q1 2025 Earnings Call Transcript
Accuray Incorporated (ARAY) Q1 2025 Earnings Call Transcript
Accuray Incorporated (ARAY) Q1 2025 Earnings Call Transcript
Positive
Zacks Investment Research
1 month ago
Accuray (ARAY) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Accuray (ARAY) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Accuray (ARAY) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Neutral
Zacks Investment Research
1 month ago
Accuray (ARAY) Reports Q1 Loss, Tops Revenue Estimates
Accuray (ARAY) came out with a quarterly loss of $0.04 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.03 per share a year ago.
Accuray (ARAY) Reports Q1 Loss, Tops Revenue Estimates
Neutral
PRNewsWire
1 month ago
Accuray Reports Fiscal 2025 First Quarter Financial Results
Strong Start to Fiscal Year, Raises 2025 Guidance MADISON, Wis. , Nov. 6, 2024 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the first quarter ended September 30, 2024.
Accuray Reports Fiscal 2025 First Quarter Financial Results
Charts implemented using Lightweight Charts™